• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

FDA-approved weight loss medications associated with weight loss at one year

byJeffrey CohenandMichael Milligan
June 15, 2016
in Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this meta-analysis, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide all had a statistically significant odds ratio of achieving 5% weight loss when compared to placebo.

2. Phentermine-topiramate had greater odds of achieving both 5% and 10% weight loss than other medications and had no increased occurrence of adverse events.

Evidence Rating Level: 2 (Good)

Study Rundown: Obesity is an important public health problem in the United States and internationally. One strategy to combat obesity is oral medications to assist individuals with weight loss. This meta-analysis included randomized controlled trials (RCTs) of the five FDA approved oral medications for obesity (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) to compare their efficacy for weight loss and side effect profiles. Outcomes were assessed at one year and the primary weight loss outcome was 5% reduction in weight (a level of weight loss deemed clinically significant by the FDA). Twenty-eight trials were included in the study, and all five agents were associated with a greater odds of achieving at least 5% weight loss when compared to placebo. Additionally, phentermine-topiramate had greater odds of achieving both 5% and 10% weight loss than other medications and had no increased occurrence of adverse events.

The strengths of this study include the use of only RCTs and the standardized data extracted from each study. However, it is limited by its use of network meta-analyses to compare agents against one another, and the primary endpoint at only 1 year. Ultimately, this study suggests that oral medications can assist individuals in achieving weight loss. However, more RCTs comparing medications directly over longer periods are needed to better understand the effect of oral medications on obesity.

Click to read the study, published today in JAMA

Relevant Reading: Long-term drug treatment for obesity: a systematic and clinical review.

RELATED REPORTS

Spirituality may help patients with weight management after bariatric surgery

The 2 Minute Medicine Podcast Episode 11

Exercise and caloric restriction reduce visceral fat in overweight adults

In-Depth [meta-analysis]: This meta-analysis compared the efficacy of the five FDA approved oral medications for obesity (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) on their effectiveness in achieving 5% weight loss and the occurrence adverse effects. For odds of achieving weight loss compared to placebo, orlistat had an OR of 2.70 (95%CI 2.34-3.09), lorcaserin an OR of 3.10 (95%CI 2.35-4.05), naltrexone-burpopion an OR of 3.95 (95%CI 3.03-5.11), phentermine-topiramate an OR of 9.22 (95%CI 6.63-12.85), and liraglutide an OR of 5.54 (95%CI 4.16-7.78). Phentermine-topiramate had greater odds of achieving both 5% and 10% weight loss at 52 weeks than other medications and was not associated with an increase in adverse events.

 

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: obesityweight loss
Previous Post

Hirschsprung disease associated with maternal obesity and preterm birth

Next Post

Neutralizing antibodies protect against SHIV infection in young macaques [PreClinical]

RelatedReports

Increasing maternal BMI linked to higher risk of cerebral palsy
Chronic Disease

Spirituality may help patients with weight management after bariatric surgery

March 29, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 11

March 23, 2023
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Chronic Disease

Exercise and caloric restriction reduce visceral fat in overweight adults

March 14, 2023
Eating in the absence of hunger linked to toddler obesity
Chronic Disease

School nutritional quality programs associated with lower BMI in children

March 6, 2023
Next Post
Government-funded initiatives provide important supports to low-income HIV patients

Neutralizing antibodies protect against SHIV infection in young macaques [PreClinical]

Lariat device for left atrial appendage exclusion associated with adverse events

2 Minute Medicine Rewind June 13, 2016

Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]

Low-cost test rapidly detects Zika virus [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options